1. Pharmacological assessment of the antineoplastic and immunomodulatory properties of a new spiroindolone derivative (7’,8’-Dimethoxy-1’,3’-dimethyl-1,2,3’,4’-tetrahydrospiro[indole-3,5’-pyrazolo[3,4-c]isoquinolin]-2-one) in chronic myeloid leukemia

   • Carlos Eduardo de Castro Alves
   • Serge L. Bogza
   • Gemilson Soares Pontes

   Research 15 July 2023 Pages: 629 - 637

   

2. Development of novel palbociclib-based CDK4/6 inhibitors exploring the back pocket behind the gatekeeper

   • Lina Li
   • Fengquan Chen
   • Xia Xue

   Research 20 July 2023 Pages: 638 - 651

   

3. Development and characterization of fused human arginase I for cancer therapy

   • Snehal Sainath Jawalekar
   • Priyanka Sugriv Kawathe
   • Abhay H. Pande

   Research 03 August 2023 Pages: 652 - 663

   

4. Enhanced antitumor and anti-metastasis by VEGFR2-targeted doxorubicin immunoliposome synergy with NK cell activation

   • Mingzhu Pan
   • Yali Liu
   • Juan Zhang

   Research 05 August 2023 Pages: 664 - 676

   

5. Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study

   • Rebecca Kristeleit
   • Alexandra Leary
   • Vivek Subbiah

   Research Open access 09 August 2023 Pages: 677 - 687

   

6. Cytotoxicity of poly-guanidine in medulloblastoma cell lines

   • Gabriel Gallo-Oller
   • Teresita Díaz de Ståhl
   • Marcela Márquez-Méndez

   Research Open access 09 August 2023 Pages: 688 - 698

   

7. Preclinical evaluation of the VEGF/Ang2 bispecific nanobody BI 836880 in nasopharyngeal carcinoma models

   • Rachel C.T. Lam
   • Connie W.C. Hui
   • Brigette B.Y. Ma

   Research 12 August 2023 Pages: 699 - 709

   

8. Efficacy, safety, and cost-minimization analysis of axicabtagene ciloleucel and tisagenlecleucel CAR T-Cell therapies for treatment of relapsed or refractory follicular lymphoma

   • Buthainah Ghanem

   Research Open access 12 August 2023 Pages: 710 - 718

   

9. Clinical characteristics of liver injury induced by immune checkpoint inhibitors in patients with advanced biliary tract carcinoma

   • Zhao Gao
   • Shikai Wu
   • Xuan Jin

   Research 17 August 2023 Pages: 719 - 726

10. Early on-treatment C-reactive protein and its kinetics predict survival and response in recurrent and/or metastatic head and neck cancer patients receiving first-line pembrolizumab

    • Markus Haas
    • Alexander Lein
    • Bernhard J. Jank

    Research Open access 21 August 2023 Pages: 727 - 736

    

11. A novel bivalent anti-c-MET/PD-1 bispecific antibody exhibits potent cytotoxicity against c-MET/PD-L1-positive colorectal cancer

    • Z. Sun
    • C. Gu
    • D. Li

    Research 30 August 2023 Pages: 737 - 750

    

12. A novel anticancer quinolone, (R)-WAC-224, has anti-leukemia activities against acute myeloid leukemia

    • Tatsuji Mino
    • Hiroshi Ureshino
    • Tatsuo Ichinohe

    Research 13 September 2023 Pages: 751 - 760

    

13. Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma

    • Kenta Yamaoka
    • Kei Irie
    • Nobuyuki Muroi

    Research Open access 18 September 2023 Pages: 761 - 767

    

14. The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis

    • Jun-yi Ke
    • Shu Huang
    • Min-chao Duan

    Review Open access 21 August 2023 Pages: 768 - 776